The global biotechnology market grew in 2002-2006 at a compound annual growth rate (CAGR) of 13.4% and generated US153.7 billion revenue in 2006, for a base of US92.9 billion in 2002.
The Americas lead the global biotechnology market, accounting for 58.3% of revenues in 2006. In the second place is the Asia-Pacific region, which generated 23.9% of total revenue in 2006.
Currently there are 139 different industries using biotechnology in their products or services. In 2006, medicine and human health sector was the one that stood out, generating US $ 96.2 billion revenue, equivalent to 62.5% of the global biotechnology market. The agriculture and food sectors contributed to revenues of $ 17.7 billion that year, corresponding to a stake of 11.5% of the biotechnology market.
Figure RE-1, shows the positioning of 35 countries in number of companies (public or private) operating in biotechnology and bioscience. It should be noted that 35 countries were analyzed and that the United States and Argentina were not included in this study.
Fonte: GLOBAL BIOECONOMY CONSULTING LLC (2006). Figure RE-1: Positioning of the countries in the number of companies operating in biotechnology and bioscience.
As shown in Figure RE-1, the country which currently has the largest number of biotechnology companies is India. Following the ranking, are highlighted, South Korea, Canada, Germany and China. Brazil appears in this ranking in 11th place.
With potential to create nearly 1 million new jobs by 2010, the biopharmaceutical industry in India may generate US $ 2 billion that year, through the development of vaccines and biogenerics, and the development of clinical services in that country can achieve the amount of approximately US $ 1.5 billion, considering the same timeframe.
These data place India in a prominent position in the global biotechnology scene. Among the most relevant aspects that contribute to the successful positioning of India, highlights the supply of highly skilled labor. India has over 300 high-level educational institutions offering courses in biotechnology, bioinformatics and life sciences, graduating around 500,000 students per year. It also has more than 100 medical schools, graduating approximately 17,000 professionals annually. More than 300,000 postgraduates and PhDs are trained annually in the areas of bioscience and engineering. The participation of the government incentives for this sector is very crucial. The state contributes to the supply of skilled workforce, provides appropriate laboratory infrastructure for the development of research in the area, encourages the creation of innovation-friendly environments (business incubators and technology parks) and creates mechanisms (regulatory frameworks) that enable the consolidation of biotechnology in various fields.
Brazil ranks 5th among the countries that most employ the biotechnology sector, whether private, public or research institutes, after China, Sweden, Japan and Denmark (Figure RE-2). Although it has great potential in terms of research and development in biotechnology, Brazil still showed no significant indicators, regarding to the incorporation of this knowledge into products and processes on an industrial scale. In fact, the information presented in the previous sections show that in the period 1998-2007, Brazil stood at very favorable position in relation to the world scientific production in the 14 topics covered in border areas, a situation that was not repeated when they were surveyed the intellectual property indicators to the same period.
Fonte: GLOBAL BIOECONOMY CONSULTING LLC (2006).
Figure RE-2: Position of countries in relation to the number of employees in companies and institutions involved in biotechnology.
The US has always remained first in biotechnology development and consolidation on almost all requirements. The country leads in R & D, reaching US285 billion, compared to US211 billion by the European Union, US114 billion invested in Japan and US85 billion in China. This high financial support has a direct impact on the country's ability to link research activities at bioscience industries.